Hyperketonemia (Acetoacetate) increases the oxidizability of LDL + VLDL in type-I diabetic patients

Free Radical Biology and Medicine

Volumn 24, Issue 1, 1998, Pages 175-181

  Jain, Sushil K ^a   McVie, Robert ^a   Jaramillo, John J ^a   Chen, Yanyun ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Acetoacetate; Diabetes; Ketosis; LDL oxidizability

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; COPPER CHLORIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; LIPID PEROXIDATION; MALE; PRIORITY JOURNAL;

ACETOACETATES; ADOLESCENT; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; KETONE BODIES; LINEAR MODELS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; OXIDATION-REDUCTION;

EID: 0031962668     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(97)00213-X     Document Type: Article

References (47)

1. Semenkovich C. F., Heinecke J. W. The mystery of diabetes and atherosclerosis. Time for a new plot. Diabetes. 46:1997;327-334.
2. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 18:1995;258-268.
3. Ruderman N. B., Williamson J. R., Brownlee M. Glucose and diabetic vascular disease. FASEB J. 6:1992;2905-2914.
4. Colwell J. A., Lopes-Virella M. F. A review of the development of large-vessel disease in diabetes mellitus. Am. J. Med. 85:(Suppl. 5A):1988;113-118.
5. Ginsberg H. N. Lipoprotein physiology in nondiabetic and diabetic states - relationship to atherogenesis. Diabetes Care. 14, 9:1991;839-855.
6. Steinbrecher U. P., Zhang H., Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Rad. Biol. Med. 9:1990;155-168.
7. Jialal I., Devaraj S. The role of oxidized low density lipoprotein in atherogenesis. J. Nutr. 126:1996;1053S-1057S.
8. Morel D. W., Chisolm G. M. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J. Lipid. Res. 30:1989;1827-1834.
9. Santanam N., Parthasarathy S. Paradoxical actions of antioxidants in the oxidation of low density lipoprotein by peroxidases. J. Clin. Invest. 95:1995;2594-2600.
10. Aviram M. Oxidative modification of low density lipoprotein and its relation to atherosclerosis. Israel J. Med. Sci. 31:1995;241-249.
11. Takata K., Horiuchi S., Araki N., Shiga M. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J. Biol. Chem. 263:1988;14819-14825.
12. Quinn M. T., Parthasarathy S., Fong L. G., Steinberg D. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA. 84:1987;2995-2998.
13. Cushing S. D., Berliner J. A., Valente A. J., Territo M. C. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA. 87:1990;5134-5138.
14. Hessler J. R., Morel D. W., Lewis L. J., Chisolm G. M. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Atherosclerosis. 3:1983;215-222.
15. Goldstein J. L., Ho Y. K., Basu S. K., Brown M. S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA. 76:1979;333-337.
16. Lyons T. J. Oxidized low density lipoproteins: A role in the pathogenesis of atherosclerosis in diabetes? Diabetic Med. 8:1991;411-419.
17. Schwartz C. J., Valente A. J., Sprague E. A., Kelley J. L., Cayatte A. J., Rozek M. M. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care. 15:1992;1156-1164.
18. Tsai E. C., Hirsch I. B., Brunzell J. D., Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 43:1994;1010-1014.
19. Rabini R. A., Fumelli P., Galassi R., Dousset N., Taus M., Ferretti G., Mazzanti L., Curatola G., Solera M. L., Valdiguie P. Increased susceptibility to lipid oxidation of low-density lipoproteins and erythrocyte membranes from diabetic patients. Metabolism. 43,12:1994;1470-1474.
20. Babiy A. V., Gebicke J. M., Sullvan D. R., Willey K. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochem. Pharmacol. 43:1992;995-1000.
21. Gugliucci A., Menini T., Stahl A. J. C. Susceptibility to copper-enhanced autoxidation of VLDL+ LDL fractions from diabetic patients. Biochem. Mol. Biol. Intl. 32:(1):1994;139-147.
22. Jenkins A. J., Klein R. L., Chassereau C. N., Hermayer K. L., Lopes-Virella M. F. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes. 43:1996;762-767.
23. Bellomo G., Maggi E., Poli M., Agosta F. G., Bollati P., Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes. 44:1995;60-66.
24. Zhang A., Vertommen J., Van Gaal L., Leeuw I. D. A rapid and simple method for measuring the susceptibility of low-density-lipoprotein and very-low-density lipoprotein to copper-catalyzed oxidation. Clin. Chim. Acta. 227:1994;159-173.
25. Esterbauer H., Gebicki J., Puhl H., Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad. Biol. Med. 13:1992;341-390.
26. Bentzen C. L., Acuff K. J., Marechal B., Rosenthal M. A., Volk M. E. Direct determination of lipoprotein cholesterol distribution with micro-scale affinity chromatography columns. Clin. Chem. 28:(7):1982;1451-1456.
27. Vinson J. A., Dabbagh Y. A., Serry M. M., Jang J. Plant flavonoids, especially tea flavonols, are powerful antioxidants using an in vitro oxidation model for heart disease. J. Agr. Food Chem. 43:1995;2800-2802.
28. Vinson J. A., Hontz B. A. Phenol antioxidant index: Comparative antioxidant effectiveness of red and white wines. J Agr. Food Chem. 43:1995;401-403.
29. Warnick G. R., Cheung M. C., Albera J. J. Comparison of current methods for high-density lipoprotein cholesterol quantitation. Clin. Chem. 25:1979;596-604.
30. Nardini M., D'Aquino M., Tomassi G., Gentili V., Felice M. D., Scaccini C. Inhibition of human low-density lipoprotein oxidation by caffeic acid and other hydroxycinnamic acid derivatives. Free Rad. Biol. Med. 19:1995;541-552.
31. Jain S. K. Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. J. Biol. Chem. 264:1989;21340-21345.
32. Artuch R., Vilaseca M. A., Farre C., Ramon F. Determination of lactate, pyruvate, β-hydroxybutyrate and acetoacetate with a centrifugal analyser. Eur. J. Clin. Chem. Clin. Biochem. 33:1995;529-533.
33. Koch D. D., Feldbruegge D. H. Optimized kinetic method for automated determination of β-hydroxybutyrate. Clin. Chem. 33:1987;1761-1766.
34. Schwartz J. G. The role of glycohemoglobin and other other proteins in diabetes managment. Diabetes Rev. 3:1995;237-257.
35. Cameron N. E., Cotter M. A., Maxfield E. K. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in nondiabetic and streptozotocin-diabetic rats. Diabetologia. 36:1993;299-304.
36. Karasu C., Dewhurst M., Stevens E. J., Tomlinson D. R. Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids. Diabetologia. 38:1995;129-134.
37. Bravenboer B., Kappelle A. C., Hamers F. P. T., van Buren T., Erkelens D. W., Gispen W. H. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. Diabetologia. 35:1992;813-817.
38. Aoki, Y.; Yanagisawa, Y.; Yazaki, K.; Oguchi, H.; Kiyosawa, K.; Furuta, S.Protective effect of vitamin E supplementation on increased thermal stability of collagen in diabetic rats. Diabetologia 913-916; 1992.
39. Hida W., Shindoh C., Satoh J., Sagara M., Kikuchi Y., Toyota T., Shirato K. N-Acetylcystein inhibits loss of diaphragm function in streptozotocin-treated rats. Am. J. Respir. Crit. Care Med. 153:1996;1875-1879.
40. Eriksson U. J., Siman C. M. Pregnant diabetic rats fed the antioxidant butylated hydroxytoluene show decreased occurrence of malformations in offspring. Diabetes. 45:1996;1497-1502.
41. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 19:1996;257-267.
42. Jain S. K., Palmer M. The effect of oxygen radicals metabolites and vitamin E on glycosylation of proteins. Free Rad. Biol. Med. 22:1997;593-596.
43. Ceriello A., Giacomello R., Stel G., Motz E., Taboga C., Tonutti L., Pirisi M., Falleti E., Bartoli E. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes. 44:1995;924-928.
44. Krane E. J. Diabetic ketoacidosis. Pediatric Clinics North America. 34:1987;935-960.
45. Champe P. C., Harvey R. A. Lippincott's illustrated reviews: Biochemistry. 1994;171-190 J. B. Lippincott Co.
46. Vignati L., Asmal A. C., Black W. L., Brink S. J., Hare J. W. Coma in Diabetes. Marble A. Joslin's diabetes mellitus. 1985;526-552 Lea and Febiger, Philadelphia.
47. Candiloros H., Muller S., Zeghari N., Donner M., Drouin P., Ziegler O. Decreased erythrocyte membrane fluidity in poorly controlled IDDM. Diabetes Care. 18:1995;549-551.